JP2019531279A5 - - Google Patents

Download PDF

Info

Publication number
JP2019531279A5
JP2019531279A5 JP2019512859A JP2019512859A JP2019531279A5 JP 2019531279 A5 JP2019531279 A5 JP 2019531279A5 JP 2019512859 A JP2019512859 A JP 2019512859A JP 2019512859 A JP2019512859 A JP 2019512859A JP 2019531279 A5 JP2019531279 A5 JP 2019531279A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512859A
Other languages
English (en)
Japanese (ja)
Other versions
JP7042804B2 (ja
JP2019531279A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/052106 external-priority patent/WO2018053447A1/en
Publication of JP2019531279A publication Critical patent/JP2019531279A/ja
Publication of JP2019531279A5 publication Critical patent/JP2019531279A5/ja
Application granted granted Critical
Publication of JP7042804B2 publication Critical patent/JP7042804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512859A 2016-09-19 2017-09-18 ピペラジンカルバメート、及びその製造と使用の方法 Active JP7042804B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662396561P 2016-09-19 2016-09-19
US62/396,561 2016-09-19
PCT/US2017/052106 WO2018053447A1 (en) 2016-09-19 2017-09-18 Piperazine carbamates and methods of making and using same

Publications (3)

Publication Number Publication Date
JP2019531279A JP2019531279A (ja) 2019-10-31
JP2019531279A5 true JP2019531279A5 (enExample) 2020-11-05
JP7042804B2 JP7042804B2 (ja) 2022-03-28

Family

ID=61619083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512859A Active JP7042804B2 (ja) 2016-09-19 2017-09-18 ピペラジンカルバメート、及びその製造と使用の方法

Country Status (6)

Country Link
US (1) US10899737B2 (enExample)
EP (1) EP3515897B1 (enExample)
JP (1) JP7042804B2 (enExample)
CN (1) CN109996790B (enExample)
ES (1) ES2892952T3 (enExample)
WO (1) WO2018053447A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター,インク. ピペラジンカルバメート、及びその製造と使用の方法
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors
CA3106510A1 (en) * 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2021061858A1 (en) * 2019-09-25 2021-04-01 Frontier Medicines Corporation Targeted autophagy conjugates and methods
MX2022005864A (es) * 2019-11-15 2022-08-16 H Lundbeck As Formas cristalinas de un inhibidor de magl.
IL297470A (en) * 2020-04-21 2022-12-01 H Lundbeck As Synthesis of a monoacylglycerol lipase inhibitor
AU2022426844A1 (en) 2021-12-29 2024-07-04 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009363A (en) 1911-07-05 1911-11-21 Albert Winnie Artificial fishing-bait.
US1057010A (en) 1913-01-14 1913-03-25 Harry L Roderick Means for controlling doors and steps of cars.
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
WO1995017439A2 (en) 1993-12-22 1995-06-29 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
JP2000500448A (ja) 1995-11-15 2000-01-18 ゼネカ リミテッド 除草性置換ピラゾール化合物
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
WO2005063698A1 (en) 2003-12-31 2005-07-14 Council Of Scientific & Industrial Research Process for preparing carbamates
CN1934097A (zh) 2004-02-18 2007-03-21 阿斯利康(瑞典)有限公司 炔基化哌嗪化合物及其作为代谢型谷氨酸受体拮抗剂的应用
JP2008521768A (ja) 2004-12-23 2008-06-26 エフ.ホフマン−ラ ロシュ アーゲー ヘテロ環式カルバミン酸誘導体、それらの製造及び医薬品としての使用
PL2937341T3 (pl) 2004-12-30 2017-11-30 Janssen Pharmaceutica N.V. Pochodne fenyloamidowe kwasu 4-(benzylo)-piperazyno-1-karboksylowego oraz związki powiązane, jako modulatory hydrolazy amidu kwasu tłuszczowego (FAAH) do leczenia lęku, bólu i innych schorzeń
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス,インコーポレーテッド C型肝炎の治療方法
JP5442448B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Fgfrインヒビターとしての二環式ヘテロ環式化合物
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
WO2010056309A2 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
KR20110131302A (ko) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 오로라 a 선택적 억제 작용을 갖는 신규한 아미노피리딘 유도체
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
EP2497082B1 (de) 2009-11-03 2013-09-04 Bayer Intellectual Property GmbH Fluorurethane als additive in einer photopolymer-formulierung
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
HUE038403T2 (hu) 2012-01-06 2018-10-29 Agios Pharmaceuticals Inc Terápiásan alkalmazható vegyületek és alkalmazási módszereik
AU2013207252B2 (en) 2012-01-06 2016-06-09 H.Lundbeck A/S Carbamate compounds and pharmaceutical compositions thereof
WO2013142307A1 (en) 2012-03-19 2013-09-26 Abide Therapeutics Carbamate compounds and of making and using same
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
CA2917050A1 (en) 2013-07-03 2015-01-08 Todd K. Jones Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2016014975A2 (en) 2014-07-25 2016-01-28 Northeastern University Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof
ES2878041T3 (es) 2015-03-18 2021-11-18 H Lundbeck As Carbamatos de piperazina y métodos para prepararlos y usarlos
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター,インク. ピペラジンカルバメート、及びその製造と使用の方法
ES2966939T3 (es) 2016-11-16 2024-04-25 H Lundbeck As Una forma cristalina de un inhibidor de MAGL
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20200022A1 (ar) 2017-08-29 2020-02-02 Lundbeck La Jolla Research Center Inc مركبات حلقية لولبية وطرق تصنيعها واستخدامها
US11332453B2 (en) 2018-05-15 2022-05-17 H. Lundbeck A/S MAGL inhibitors

Similar Documents

Publication Publication Date Title
JP2019531279A5 (enExample)
JP2018529650A5 (enExample)
JP2019524883A5 (enExample)
JP2020530487A5 (enExample)
JP2020532547A5 (enExample)
JP2019034943A5 (enExample)
JP2020502047A5 (enExample)
JP2014511891A5 (enExample)
JP2020532545A5 (enExample)
JP2016121196A5 (enExample)
JP2020529994A5 (enExample)
JP2014513110A5 (enExample)
JP2018519323A5 (enExample)
JP2019535672A5 (enExample)
JP2017538689A5 (enExample)
JP2012529535A5 (enExample)
JP2014015465A5 (enExample)
JP2017530959A5 (enExample)
JP2014193925A5 (enExample)
JP2009542595A5 (enExample)
JP2017523225A5 (enExample)
JP2020521767A5 (enExample)
JP2015520140A5 (enExample)
JP2016525130A5 (enExample)
JP2020521766A5 (enExample)